alexa Abstract | Long-term Follow-up of Pegylated Liposomal Doxorubicin and Oxaliplatin in Recurrent Ovarian Cancer
ISSN: 2329-6771

Journal of Integrative Oncology
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article Open Access


Oxaliplatin (LOHP) and pegylated liposomal doxorubicin (PLD) are active single agents in recurrent ovarian cancer (ROC). In this phase II study we explored safety and activity of combined LOHP and PLD in the treatment of ROC. Eligible patients had had disease recurrence following a paclitaxel/ carboplatin regimen or following cisplatinum or non-platinum-based second line chemotherapy. Other eligibility criteria were a performance status ≤ 2 and a life expectancy > 3 months. Treatment consisted of 120 mg/m2 LOHP and 40 mg/m2 PLD, given over 2 days, every 3 weeks. Forty-six patients with ROC were entered into the study between 10/2001 and 10/2005; 67.5% of patients were platinum-sensitive. Toxicity was moderate, with grade 3 or 4 neutropenia in 2% of patients, and grade 2 PPE in 7% of patients. Overall response rate was 67.5%. Median progression-free survival (PFS) was 27.5 months, while median overall survival was 44 months. We conclude that LOHP and PLD are active in ROC, and can be safely administered in pre-treated patients

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Francesco Recchia, Giampiero Candeloro and Silvio Rea


Recurrent ovarian cancer, Salvage chemotherapy, Pegylated liposomal doxorubicin, Oxaliplatin, Molecular Oncology, Interventional Oncology, Oncology Nutrition

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version